The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Novo Nordisk A/S shares fell over 4% premarket Friday, heading for lows last seen in early August, amid concerns over pricing ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

The stock is down 3%, or $2.81, to $80.26 in premarket trading.Stay Ahead of the Market:Discover outperforming stocks and invest smarter with ...

Popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated ...